Molecular Informatics Signs Licensing Agreement with Genzyme Corp.SANTA FE Santa Fe, city, Argentina Santa Fe, city (1991 pop. 341,000), capital of Santa Fe prov., NE Argentina, a river port near the Paraná, with which it is connected by canal. , N.M.--(BUSINESS WIRE)--July 8, 1997--Molecular Informatics Inc. (MII 1. (body) MII - A consortium of Microsoft, IBM, and Intel. 2. (storage) MII - A broadcast component video tape format licensed by Panasonic. ), a leading developer of bioinformatics software used in drug discovery and development, patient stratification, and molecular diagnostics, has signed a licensing agreement with Genzyme Corp. for MII's BioMerge(TM) software. BioMerge combines object-oriented and relational database relational database Database in which all data are represented in tabular form. The description of a particular entity is provided by the set of its attribute values, stored as one row or record of the table, called a tuple. technologies to provide an enterprise-wide software system used by pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. to process, manage, integrate and analyze genomic information for drug discovery and development. The agreement allows Genzyme early access to MII technology, consulting and product services. Terms of the agreement were not disclosed. BioMerge is exclusively distributed worldwide by MDL MDL - (Originally "Muddle"). C. Reeve, Carl Hewitt and Gerald Sussman, Dynamic Modeling Group, MIT ca. 1971. Intended as a successor to Lisp, and a possible base for Planner-70. Basically LISP 1.5 with data types and arrays. Information Systems of San Leandro, Calif. to the life sciences discovery community. Clinical and diagnostic applications of MII's bioinformatics technology are directly marketed by MII. Genzyme is involved in a number of gene-based medicine areas which include programs in genetic diagnostics, gene therapy, cancer genetics, transgenics trans·gen·ics n. (used with a sing. or pl. verb) The study of or methodology used to create transgenic animals or plants. and genomics. To effectively generate, compare and analyze the large volumes of genetic data involved in these programs, a specialized and sophisticated bioinformatics tool is necessary. The MII bioinformatics technology will enhance and support Genzyme General's (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :GENZ) MASDA MASDA Multiplex Allele-Specific Diagnostic Assay MASDA Model and Simulation Decision Aid (SM) (Multiple Allele-Specific Diagnostic Assay) technology and Genzyme Molecular Oncology's SAGE (Serial Analysis of Gene Expression Serial analysis of gene expression (SAGE) is a technique used by molecular biologists to produce a snapshot of the messenger RNA population in a sample of interest. The original technique was developed by Dr. ) technology. MASDA is used to analyze hundreds of patient DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. samples hundreds of mutations on one or more genes at the same time. SAGE is a powerful genomics tool which detects and quantitates gene expression levels in different tissues. The BioMerge software helps compare the genetic data generated by MASDA and SAGE to public genomic databases. "We are excited about the rapid expansion of our gene-based medicine programs at Genzyme," said Katherine W. Klinger, vice president, Science for Genzyme's Genetics unit. "We are particularly pleased that we will be working with Molecular Informatics to establish a powerful, comprehensive, leading edge bioinformatics system that will be integral in our total effort." "We are pleased to be working with Genzyme to develop a bioinformatics system in which MII expertise and products will be key elements," said Dr. Edward Cantrall, president and chief executive officer of MII. "With its strong positions in diagnostics, Genzyme represents an ideal strategic partner with whom Molecular Informatics can develop a state-of-the-art system for the management of genetic and related test data," Cantrall added. The BioMerge software system simplifies the complex task of analyzing genomic data from multiple sources. BioMerge is a client-server management and integration system that combines relational and object-oriented technology to provide flexibility and high performance in manipulating genome-scale data. In addition, BioMerge users can subscribe to Genomes Today(TM), MII's daily update service, which provides users with newly published genomic data from around the world. Genzyme Corp., a biotechnology and health care products company, focuses on developing innovative products and services for major unmet medical needs. Genzyme General develops and markets pharmaceuticals, genetic diagnostic services diagnostic services, n.pl the imaging and laboratory capabilities available for determining the cause of an illness. , and diagnostic, surgical and specialty therapeutic products. A division of Genzyme Corp., Genzyme General has its own common stock intended to reflect its value and track its performance. Genzyme Molecular Oncology develops molecular approaches to cancer diagnosis and therapy through genomics, gene therapy, genetic diagnostics, and a small-molecule combinatorial chemistry drug discovery program. Genzyme Molecular Oncology has its own common stock, which is not yet publicly traded, intended to reflect its value and track its performance. Molecular Informatics Inc. is a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. based in Santa Fe. MII is a pioneer in the development of bioinformatics software used in high-throughput sequencing, drug discovery and development, clinical trials and molecular diagnostics. In addition, MII develops and markets subscription genomic databases and provides a full range of professional services. Interested parties can contact MII at 505/995-4475 or visit MII's World Wide Web site at http://www.molinfo.com . CONTACT: Molecular Informatics Inc., Santa Fe J. Maverick Granger, 505/995-4425 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion